Patient population
Women with abnormal cervical cancer screening results were asked to participate in this study. The inclusion criteria included: 1) women over 21 years of age; 2) infected with high-risk strains of HPV (including type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and/or with abnormal cytological examination (atypical squamous cells of undetermined significance, ASCUS or worse); 3) were willing and able to sign the informed consent. The exclusion criteria included:1) women were breast-feeding or pregnant; 2) allergy to TMTP1-PEG-ICG, acetic acid, Lugol’s iodine or alcohol; 3) diagnosis of vaginitis or other sexually transmitted diseases makes it unsuitable for biopsy sampling; 4) with severe heart failure, liver insufficiency or renal insufficiency; 5) participated in another clinical trial with an investigational drug within 3 months. In addition, patients with the vaginal lesions were not included in the final statistical analysis.